Skip to main content
. Author manuscript; available in PMC: 2011 Nov 15.
Published in final edited form as: Am J Transplant. 2011 Apr 5;11(5):923–935. doi: 10.1111/j.1600-6143.2011.03492.x

Figure 9. Anti-LFA-1 monotherapy does not induce long-term allograft survival in CCR5−/− recipients.

Figure 9

Groups of 4–5 B6.CCR5−/− or B6.μMT−/−/CCR5−/− mice were treated with 200 μg control rat IgG or with anti-LFA-1 mAb on days −1 and 0. (A) The treated mice received complete MHC mismatched A/J cardiac allografts on day 0 and graft survival was followed daily by abdominal palpation and rejection confirmed by laparotomy. p < 0.05 vs. survival in control IgG CCR5−/− and vs. untreated μMT−/−/CCR5−/− recipients. (B) Prepared sections were stained with hematoxylin-eosin or with C4d-specific antibodies for immunohistochemical analyses. Sections shown are representative of 3–4 grafts analyzed in each group. Magnification, 200x.